Phase I-II

Suppliers

Related News

Avoca CEO Patricia Leuchten on stage at the Avoca Quality Consortium (AQC) summit.

Pace of change in clinical trial landscape has become rapid, says Avoca CEO

The First-in-Human trial demonstrated that the novel challenge agent had high attack rates of up to 100%. (Image: iStock/bodym)

SGS completes Ph I trial of new influenza virus

CRO turnover increased from 20.1% in 2015 to 22% last year. (Image: iStock/PhotoProdra)

Report: CRO turnover creates loss of continuity

See More Headlines